Lazolvan - Instructions For Use, Price, Syrup, Injection Solution

2024 Author: Rachel Wainwright | [email protected]. Last modified: 2023-12-15 07:39

Lazolvan

Lazolvan: instructions for use and reviews

1. 1. Release form and composition
2. 2. Pharmacological properties
3. 3. Indications for use
4. 4. Contraindications
5. 5. Method of application and dosage
6. 6. Side effects
7. 7. Overdose
8. 8. Special instructions
9. 9. Application during pregnancy and lactation
10. 10. Use in childhood
11. 11. In case of impaired renal function
12. 12. For violations of liver function
13. 13. Drug interactions
14. 14. Analogs
15. 15. Terms and conditions of storage
16. 16. Terms of dispensing from pharmacies
17. 17. Reviews
18. 18. Price in pharmacies

Latin name: Lasolvan

ATX code: R05CB06

Active ingredient: ambroxol (ambroxol)

Producer: Instituto De Angeli (Italy), Boehringer Ingelheim Ellas (Greece), Bolder Arzneimittel GmbH & Co. KG (Germany), Delpharm Reims (France)

Description and photo update: 2019-13-08

Prices in pharmacies: from 136 rubles.

Buy

Lazolvan is an expectorant and mucolytic drug.

Release form and composition

Lazolvan is available in the following dosage forms:

• Lozenges: round, light brown, with the smell of peppermint (in blisters of 10 pcs., 1, 2 or 4 blisters in a cardboard box);
• Tablets: round, slightly yellowish or white, flat on both sides, with beveled edges, on one side there is a dividing line and the inscription "67C" squeezed out on both sides of it, on the other - the company symbol (in blisters of 10 pcs., 2 or 5 blisters in a cardboard box);
• Syrup: almost colorless or colorless, almost transparent or transparent, with the smell of wild berries (15 mg / 5 ml) or strawberry smell (30 mg / 5 ml), slightly viscous (in dark glass bottles of 100, 200 or 250 ml per complete with measuring cup or without it, 1 bottle in a cardboard box);
• Solution for oral administration and inhalation: transparent, slightly brownish or colorless (in dark glass bottles of 100 ml, complete with a dosage cup or beaker, 1 bottle in a cardboard box).

1 Lazolvan lozenge contains:

• Active ingredient: ambroxol - 15 mg (as hydrochloride);
• Auxiliary components: acacia gum - 850 mg, sorbitol - 307.4 mg, Karion 83 (mannitol, sorbitol, hydrogenated hydrolyzed starch) - 614.8 mg, peppermint leaf oil - 10 mg, rod-shaped eucalyptus leaf oil - 2 mg, saccharinate sodium - 1.8 mg, liquid paraffin (purified mixture of liquid saturated hydrocarbons) - 2.4 mg, purified water - 196.6 mg.

The composition of 1 tablet Lazolvan includes:

• Active ingredient: ambroxol - 30 mg (as hydrochloride);
• Auxiliary components: lactose monohydrate - 171 mg, dried corn starch - 36 mg, colloidal silicon dioxide - 1.8 mg, magnesium stearate - 1.2 mg.

5 ml of Lazolvan syrup contains:

• Active ingredient: ambroxol - 15 or 30 mg (as hydrochloride);
• Auxiliary components (15/30 mg in 5 ml, respectively): benzoic acid - 8.5 / 8.5 mg, hydroxyethyl cellulose (hyetellose) - 10/10 mg, acesulfame potassium - 5/5 mg, liquid sorbitol (non-crystallizing) - 1750/1750 mg, glycerol 85% - 750/750 mg, vanilla flavor 201629 - 3/3 mg, purified water - 3047.5 / 3031.5 mg, forest berry flavor PHL-132195 - 11 mg (for syrup 15 mg / 5 ml) or strawberry-cream flavor PHL-132200 - 12 mg (for syrup 30 mg / 5 ml).

The composition of 1 ml of solution for oral administration and inhalation of Lazolvan includes:

• Active ingredient: ambroxol - 7.5 mg (as hydrochloride);
• Auxiliary components: citric acid monohydrate - 2 mg, sodium hydrogen phosphate dihydrate - 4.35 mg, sodium chloride - 6.22 mg, benzalkonium chloride - 0.225 mg, purified water - 989.705 mg.

Pharmacological properties

Pharmacodynamics

Research data show that ambroxol, which is the active ingredient in Lazolvan, causes an increase in secretion in the respiratory tract. As a result of exposure to the drug, the production of pulmonary surfactant and ciliary activity are enhanced. These effects stimulate mucus flow and transport (mucociliary clearance), resulting in intense sputum discharge and relief of cough. In the treatment of chronic obstructive pulmonary disease during long-term therapy with Lazolvan (for 2 months or more), the number of exacerbations significantly decreased. A significant decrease in the duration of exacerbations and the number of days of antibiotic therapy was recorded.

Pharmacokinetics

All dosage forms of immediate release ambroxol are characterized by rapid and almost complete absorption (there is a linear dependence of absorption on dose). When taken orally, the maximum plasma concentration of Ambroxol is reached after 60–150 minutes. The volume of distribution is 552 liters. The binding of ambroxol to plasma proteins in the therapeutic concentration range is approximately 90%.

When administered orally, the transition of the active substance from the blood to the tissue occurs quickly. The highest concentrations of ambroxol are observed in the lungs. About 30% of an oral dose undergoes the primary liver passage process. In the course of studies on human liver microsomes, it has been proven that the predominant isoform is the CYP3A4 isoenzyme. It is responsible for the metabolism of the active substance to dibromantranilic acid. The remaining amount is metabolized in the liver, mainly by glucuronidation and by partial degradation (approximately 10%) to dibromantranilic acid and additional metabolites in small amounts. The terminal half-life is 10 hours. The total clearance is up to 660 ml / min, with about 8% of the total clearance being renal clearance. In studies by the method of radioactive labeling, it is calculated that as a result of taking a single dose of ambroxol over the next 5 days, approximately 83% of the dose taken is excreted in the urine.

A clinically significant effect of gender and age on the pharmacokinetics of ambroxol has not been recorded, so there is no reason to select a dosage based on these characteristics.

Indications for use

Lazolvan is prescribed for the treatment of the following acute and chronic diseases of the respiratory tract, which occur with the release of viscous sputum:

• Bronchiectasis;
• Pneumonia;
• Bronchitis in acute and chronic course;
• Bronchial asthma, proceeding with difficulty in sputum discharge;
• Chronic obstructive pulmonary disease.

Contraindications

• First trimester of pregnancy and lactation;
• Hypersensitivity to drug components.

Lazolvan should be used with caution in pregnant women in II-III trimeters, as well as in renal and / or hepatic insufficiency.

Children, depending on the dosage form of Lazolvan, can be taken:

• Lozenges and syrup 30 mg / 5 ml: from 6 years old;
• Tablets: from 18 years old.

In lozenges, in terms of the maximum recommended daily dose (90 mg), contains 3200 mg of sorbitol, therefore, patients with rare hereditary fructose intolerance should not take Lazolvan in this dosage form.

Lazolvan in the form of tablets is contraindicated for patients with lactase deficiency, lactose intolerance and glucose-galactose malabsorption.

Lazolvan syrup should not be taken by patients with hereditary fructose intolerance.

Instructions for the use of Lazolvan: method and dosage

Lazolvan is used internally or by inhalation.

Inside, the drug can be taken regardless of the time of the meal.

Lozenges should be slowly dissolved in the mouth, tablets should be taken with liquid, the solution can be diluted in juice, tea, milk or water.

As a rule, Lazolvan inside is prescribed:

• Lozenges: adults and children from 12 years old - 3 times a day, 2 lozenges; children 6-12 years old - 2-3 times a day, 1 lozenge;
• Tablets: 3 times a day, 1 tablet; to enhance the therapeutic effect, it is possible to increase the daily dose (2 tablets 2 times a day);
• Syrup 15 mg / 5 ml: adults and children from 12 years old - 3 times a day, 10 ml; children 6-12 years old - 2-3 times a day, 5 ml; children 2-6 years old - 3 times a day, 2.5 ml; children under 2 years old - 2 times a day, 2.5 ml;
• Syrup 30 mg / 5 ml: adults and children from 12 years old - 3 times a day, 5 ml; children 6-12 years old - 2-3 times a day, 2.5 ml;
• Oral solution (1 ml = 25 drops): adults and children from 12 years old - 3 times a day, 100 drops; children 6-12 years old - 2-3 times a day, 50 drops; children 2-6 years old - 3 times a day, 25 drops; children under 2 years old - 2 times a day, 25 drops.

Inhalation Lazolvan is usually prescribed:

• Adults and children from 6 years old - 1-2 inhalations, 2-3 ml of solution per day;
• Children under 6 years of age - 1-2 inhalations of 2 ml of solution per day.

For inhalation, you can use any modern equipment designed for this (except for steam inhalers). To ensure optimal hydration during inhalation, Lazolvan must be mixed with 0.9% sodium chloride solution in a 1: 1 ratio. Since during inhalation therapy, a deep breath can lead to the development of a cough, inhalations must be carried out while maintaining the normal breathing rhythm. Before the procedure, the Lazolvan inhalation solution is recommended to be warmed up to body temperature. Patients with bronchial asthma are recommended to carry out inhalation after taking bronchodilator drugs, which will help to avoid nonspecific irritation of the respiratory tract and their spasm.

If the symptoms of the disease persist for 4-5 days from the moment you start taking Lazolvan, it is recommended to consult a doctor.

Side effects

As a rule, Lasolvan is well tolerated.

During therapy, the following side effects may develop:

• Gastrointestinal tract: often - nausea, decreased sensitivity in the esophagus or mouth; infrequently - diarrhea, dyspepsia, heartburn, vomiting, pain in the upper abdomen, dryness of the mucous membrane of the throat and mouth;
• Nervous system: often - a violation of taste;
• Immune system, skin and subcutaneous tissues: rarely - urticaria, rash, angioedema, anaphylactic reactions (including anaphylactic shock), itching and other allergic reactions.

Overdose

The specific symptoms of an overdose of Lazolvan in humans have not been described.

There is evidence of a medical error and / or accidental overdose, as a result of which the symptoms of side effects known for this drug were recorded: dyspepsia, nausea, vomiting, diarrhea, abdominal pain. In some cases, there is a need for symptomatic therapy.

Treatment: you should artificially induce vomiting, rinse the stomach for 1-2 hours after taking the drug. Symptomatic therapy is also indicated.

special instructions

You should not combine Lazolvan with antitussive drugs that impede the excretion of sputum.

In patients with severe skin lesions (toxic epidermal necrolysis or Stevens-Johnson syndrome) in the early phase, fever, rhinitis, body pain, sore throat and cough may appear. With symptomatic therapy, it is possible to erroneously prescribe mucolytic drugs such as Lazolvan. There are isolated reports of the identification of toxic epidermal necrolysis and Stevens-Johnson syndrome, which coincided with his appointment, but there is no causal relationship with the administration of Lazolvan.

In the event of the development of the above syndromes, you must interrupt the use of the drug and immediately seek help from a doctor.

With functional disorders of the kidneys, Lazolvan can be used only as directed by a doctor.

The composition of 1 tablet contains 162.5 mg of lactose, in the maximum daily dose (4 tablets) - 650 mg of lactose.

Sorbitol, which is part of the syrup, may have a slight laxative effect. The maximum recommended daily dose of syrup contains 5 g (in 20 ml of syrup 30 mg / 5 ml) or 10.5 g (in 30 ml of syrup 15 mg / 5 ml) of sorbitol.

The solution for oral administration and inhalation contains a preservative benzalkonium chloride, which, during inhalation, can cause bronchospasm in patients with increased airway reactivity. It is not recommended to mix the solution with alkaline solutions and cromoglycic acid. An increase in the pH value of the solution above 6.3 can lead to precipitation of the active substance or the appearance of opalescence.

Patients who follow a diet with a low sodium content should take into account that the recommended daily dose (for adults and children from 12 years old) of Lazolvan in the form of a solution for oral administration and inhalation contains 42.8 mg of sodium.

Application during pregnancy and lactation

Ambroxol crosses the placental barrier. In the course of preclinical studies, no direct or indirect adverse effect of the drug on the course of pregnancy, embryonic / fetal, postnatal development and labor was revealed.

Extensive clinical experience with the use of the drug from the 28th week of pregnancy showed no evidence of a negative effect of the drug on the fetus, however, when using Lazolvan during gestation, the usual precautions should be followed. The drug is not recommended to be taken in the first trimester of pregnancy. Use in the II or III trimesters is allowed only in cases where the potential risk to the fetus is lower than the potential benefit to the mother.

Ambroxol is excreted in breast milk. There are no data on the development of undesirable effects in children who were breastfed, but it is not recommended to use Lazolvan during lactation.

In the course of preclinical studies of Ambroxol, a negative effect on fertility was not revealed.

Pediatric use

When treating children under the age of 12 months, Lazolvan is used only in the form of a solution. In such cases, it is necessary to ensure constant medical supervision.

According to the instructions, Lazolvan in the form of tablets is prohibited for the treatment of children under the age of 18, in the form of lozenges - up to 6 years.

With impaired renal function

In case of renal failure, the drug should be used with caution.

For violations of liver function

In hepatic impairment, the drug should be used with caution.

Drug interactions

There are no data on clinically significant undesirable interactions of Lazolvan with other drugs.

Lazolvan increases the penetration into the bronchial secretions of drugs such as cefuroxime, amoxicillin and erythromycin.

Analogs

Lazolvan's analogs are: Ambroxol, Ambroxol Vramed, Ambrobene, Medox, Ambrohexal, Bronhorus, Halixol, Flavamed, Lazolvan Uno.

Terms and conditions of storage

Store in a dark place, out of reach of children.

Shelf life:

• Lozenges - 3 years at temperatures up to 30 ° C;
• Tablets - 5 years at temperatures up to 30 ° C;
• Syrup - 3 years at temperatures up to 25 ° C;
• Solution for oral administration and inhalation - 5 years at temperatures up to 25 ° C.

Terms of dispensing from pharmacies

Available without a prescription.

Reviews about Lazolvan

Reviews about Lazolvan are mostly positive. Users note that within a few days after taking the drug, there is an improvement in bronchitis and other diseases. According to parental reviews, Lazolvan in the form of a solution for inhalation and syrup has proven itself well in the treatment of children.

Also, some users report the development of side effects (diarrhea, allergic reactions from the skin).

The price of Lazolvan in pharmacies

The approximate price for Lazolvan is:

• lozenges (pack of 20) - 211 rubles;
• tablets: 50 pcs. - 290 rubles., 20 pcs. - 170 rubles;
• syrup in bottles of 100 ml: 15 mg / 5 ml - 215 rubles, 30 mg / 5 ml - 280 rubles;
• solution for oral administration and inhalation of 7.5 mg / ml in 100 ml vials - 380 rubles.

Lazolvan: prices in online pharmacies

Drug name Price Pharmacy

Lazolvan 30 mg tablets 20 pcs. 136 RUB Buy

Lazolvan 15 mg / 5 ml syrup with wild berry flavor 100 ml 1 pc. 159 r Buy

Lazolvan tablets 30mg 20 pcs. 167 r Buy

Lazolvan syrup for children with the taste of wild berries 15mg / 5ml fl. 100ml No. 1 188 r Buy

Lazolvan Max 75 mg capsules of prolonged action 10 pcs. 204 RUB Buy

Lazolvan 30 mg / 5 ml syrup 100 ml 1 pc. 207 r Buy

Lazolvan Fito 150 mg / ml syrup with 100 ml dosing cup 1 pc. 209 RUB Buy

Lazolvan syrup 30mg / 5ml fl. 100ml No. 1 213 r Buy

Lazolvan phyto syrup 150mg / ml fl. 100ml 215 RUB Buy

Lazolvan 30 mg tablets 50 pcs. 225 RUB Buy

Lazolvan tablets 30mg 50 pcs. 231 RUB Buy

Lazolvan Max capsules prolonged action 75mg 10 pcs. 245 RUB Buy

Lasolvan Rino 1.18 mg / ml 82 μg / dose nasal spray 10 ml 1 pc. RUB 250 Buy

Lasolvan Rino nasal spray dosed 82 mcg / dose vial. 10ml 316 RUB Buy

Lazolvan 7.5 mg / ml solution for oral administration and inhalation 100 ml 1 pc. 335 RUB Buy

Lazolvan solution for ing and vnutr. approx. 7.5mg / ml 100ml 363 r Buy

See all offers from pharmacies

Anna Kozlova Medical journalist About the author

Education: Rostov State Medical University, specialty "General Medicine".

Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!